eli lilly retatrutide study Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Eli Lilly's Retatrutide Achieves 20%

Patients typically report feeling satisfied with smaller portions and experiencing reduced hunger between meals, which facilitates the caloric deficit necessary for weight loss

Heres what our registered dietitian Katie Hoehn had to say about GLP-1s and diet: Since GLP-1 medications delay gastric emptying and reduce appetite, they often lead to lower overall calorie intake, which can put individuals at risk for nutrient deficiencies

Research suggests that fat tissue is associated with higher estrogen levels, which may contribute to tumor growth

MOTs-C Cognitive Enhancement Peptides that enhance cognition by supporting memory, focus, mental clarity, and overall brain function

Researchers are mapping the specific hypothalamic and brainstem circuits involved in its appetite-suppressing effects and how these interact with other central metabolic regulators